AVXT: AI 评分 50/100 — AI 分析 (4月 2026)

AVAX Technologies, Inc. is a development stage biopharmaceutical company focused on autologous cell vaccine technologies for cancer treatment. Their product candidates include M-VAX, O-VAX, and LungVax, targeting melanoma, ovarian cancer, and non-small cell lung cancer, respectively.

Key Facts: AI Score: 50/100 Sector: Healthcare

公司概况

概要：

AVAX Technologies, Inc. is a development-stage biopharmaceutical company specializing in autologous cell vaccine technologies for cancer treatment, including melanoma, ovarian cancer, and non-small cell lung cancer. With Phase II clinical trials completed for M-VAX and O-VAX, the company operates in a competitive biotechnology landscape.

AVXT是做什么的？

AVAX Technologies, Inc., founded in 1990 and based in Philadelphia, Pennsylvania, is a biopharmaceutical company in the development stage. The company focuses on autologous cell vaccine technologies designed for cancer treatment. Its origins trace back to Walden Laboratories, Inc., before rebranding to AVAX Technologies, Inc. in March 1996. The company's pipeline features product candidates like M-VAX, intended for melanoma treatment, and O-VAX, targeting ovarian cancer, both of which have completed Phase II clinical trials. Additionally, AVAX Technologies is developing LungVax for the treatment of non-small cell lung cancer. These autologous cell vaccines are designed to utilize a patient's own cells to stimulate an immune response against cancer cells. As a development stage company, AVAX Technologies is currently focused on advancing its product candidates through the clinical trial process. The company operates within the biotechnology sector, which is characterized by high research and development costs, regulatory hurdles, and competition from other companies developing cancer therapies. With a small team of 9 employees, AVAX Technologies seeks to make an impact in the field of cancer immunotherapy.

AVXT的投资论点是什么？

AVAX Technologies, Inc. presents a high-risk, high-reward investment profile typical of development-stage biotechnology companies. The company's focus on autologous cell vaccine technologies for cancer treatment offers potential for significant returns if its product candidates successfully navigate clinical trials and regulatory approval. However, the company's negative profit margin of -1038.8% underscores its reliance on future funding or partnerships to sustain operations. Key value drivers include the successful advancement of M-VAX, O-VAX, and LungVax through clinical trials. Upcoming clinical trial results will be critical catalysts. The company's small size and limited resources, with only 9 employees, pose operational risks. Investors should closely monitor clinical trial progress, regulatory milestones, and the company's ability to secure additional funding.

AVXT在哪个行业运营？

AVAX Technologies, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, stringent regulatory requirements, and high levels of competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like AVAX Technologies, Inc. are focused on developing novel therapies, including immunotherapies and cell-based vaccines, to address unmet needs in cancer treatment. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in this lucrative sector.

Biotechnology

Healthcare

AVXT有哪些增长机遇？

Advancement of LungVax for Non-Small Cell Lung Cancer: Lung cancer represents a significant market opportunity, with non-small cell lung cancer (NSCLC) being the most prevalent form. Successful clinical trials and subsequent regulatory approval for LungVax could drive substantial revenue growth for AVAX Technologies. The timeline for this growth opportunity depends on the pace of clinical development and regulatory review, potentially spanning several years. The addressable market is substantial, with the global lung cancer therapeutics market projected to reach billions of dollars.
Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies could provide AVAX Technologies with access to additional funding, expertise, and resources to accelerate the development and commercialization of its product candidates. These collaborations can take the form of licensing agreements, joint ventures, or co-development partnerships. The timeline for securing such partnerships is uncertain but could occur within the next 1-3 years. Successful partnerships would validate the company's technology and enhance its market position.
Expansion of Autologous Cell Vaccine Technology to Other Cancer Types: AVAX Technologies could leverage its autologous cell vaccine technology platform to develop new product candidates for other types of cancer beyond melanoma, ovarian cancer, and non-small cell lung cancer. This would diversify the company's pipeline and expand its addressable market. The timeline for this expansion depends on the availability of funding and the success of preclinical research. The market for cancer vaccines is growing, driven by advances in immunotherapy and personalized medicine.
Out-Licensing of M-VAX and O-VAX: While AVAX Technologies continues to develop M-VAX and O-VAX, the company could explore out-licensing these product candidates to other companies for further development and commercialization. This would generate upfront revenue and potential milestone payments, providing AVAX Technologies with additional capital to invest in its other programs. The timeline for out-licensing depends on the attractiveness of the product candidates and the willingness of other companies to acquire the rights. The terms of any out-licensing agreement would vary depending on the specific circumstances.
Securing Grant Funding and Government Support: AVAX Technologies could pursue grant funding from government agencies and non-profit organizations to support its research and development activities. These grants can provide non-dilutive funding, reducing the company's reliance on equity financing. The timeline for securing grant funding is uncertain and depends on the availability of funds and the competitiveness of the applications. Successful grant applications would validate the company's technology and provide valuable resources for its development programs.

AVAX Technologies, Inc. operates in the high-growth biotechnology sector, focusing on innovative cancer treatment solutions.
The company's product candidates, including M-VAX and O-VAX, have completed Phase II clinical trials, indicating some progress in development.
AVAX Technologies, Inc. has a high gross margin of 100.0%, but this is offset by a significant negative profit margin of -1038.8%, highlighting its development stage and high R&D expenses.
The company's market capitalization is $0.00B, reflecting its early stage and speculative nature.
AVAX Technologies, Inc. has a beta of -55.48, indicating a high degree of volatility and potential for large price swings.

AVXT提供哪些产品和服务？

Develop autologous cell vaccine technologies for cancer treatment.
Focus on creating personalized cancer vaccines using a patient's own cells.
Develop M-VAX for the treatment of melanoma.
Develop O-VAX for the treatment of ovarian cancer.
Develop LungVax for the treatment of non-small cell lung cancer.
Conduct clinical trials to evaluate the safety and efficacy of their vaccine candidates.
Seek regulatory approval for their products from agencies like the FDA.

AVXT如何赚钱？

Develop and patent autologous cell vaccine technologies.
Conduct clinical trials to demonstrate safety and efficacy.
Seek regulatory approval for their vaccine products.
Potentially partner with larger pharmaceutical companies for commercialization.

Cancer patients seeking innovative treatment options.
Oncologists and medical professionals who treat cancer patients.
Hospitals and cancer centers that administer cancer therapies.
Potential pharmaceutical partners for licensing or co-development agreements.

Proprietary autologous cell vaccine technology.
Patents protecting their vaccine candidates and methods.
Clinical data supporting the safety and efficacy of their products.
Expertise in personalized cancer vaccine development.

什么因素可能推动AVXT股价上涨？

Upcoming: Clinical trial results for LungVax.
Upcoming: Potential partnerships with pharmaceutical companies.
Ongoing: Research and development of new cancer vaccine candidates.
Ongoing: Efforts to secure grant funding and government support.

AVXT的主要风险是什么？

Potential: Clinical trial failures or delays.
Potential: Regulatory hurdles and approval delays.
Ongoing: Competition from other cancer therapies.
Ongoing: Inability to secure additional funding.
Potential: Limited liquidity due to OTC market trading.

AVXT的核心优势是什么？

Proprietary autologous cell vaccine technology.
Product candidates in Phase II clinical trials.
Focus on personalized cancer treatment.
Experienced leadership in biotechnology.

AVXT的劣势是什么？

Development stage company with no approved products.
Limited financial resources and small employee base.
High reliance on successful clinical trial outcomes.
Negative profit margin and dependence on external funding.

AVXT有哪些机遇？

Advancement of LungVax into later-stage clinical trials.
Partnerships with larger pharmaceutical companies.
Expansion of technology to other cancer types.
Out-licensing of M-VAX and O-VAX.

AVXT面临哪些威胁？

Clinical trial failures or delays.
Regulatory hurdles and approval delays.
Competition from other cancer therapies.
Inability to secure additional funding.

AVXT的竞争对手是谁？

Braintronics AG — Focuses on medical technology, including neuromodulation. — (BRAXF)
DNAGroup Inc. — Operates in the biotechnology sector with a focus on DNA-based technologies. — (DNAG)
Inlab, Inc. — Develops and markets medical devices and technologies. — (INLB)
iPath S&P Pan Asia Infrastructure Index ETN — Offers exposure to infrastructure companies in the Pan-Asia region. — (IPAH)
Jin Medical International Ltd — Manufactures and sells wheelchairs and mobility assistive devices. — (JNHMF)

Key Metrics

MoonshotScore: 50/100

Company Profile

CEO: Adele Sommerfeld
Headquarters: Philadelphia, US
Employees: 9
Founded: 1997

AI Insight

AI analysis pending for AVXT

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does AVAX Technologies, Inc. do?

AVAX Technologies, Inc. is a development stage biopharmaceutical company focused on creating autologous cell vaccine technologies for the treatment of cancer. They are working on personalized cancer vaccines using a patient's own cells to stimulate the immune system to fight cancer. Their main product candidates include M-VAX for melanoma, O-VAX for ovarian cancer, and LungVax for non-small cell lung cancer. The company is currently focused on advancing these candidates through clinical trials and seeking regulatory approval.

What do analysts say about AVXT stock?

AI analysis is pending for AVXT stock. Generally, development-stage biotechnology companies like AVAX Technologies, Inc. are viewed as high-risk, high-reward investments. The success of the company hinges on the outcomes of its clinical trials and its ability to secure funding. Investors should carefully consider the risks and potential rewards before investing in AVXT. Key valuation metrics are difficult to assess at this stage due to the lack of revenue and earnings.

What are the main risks for AVXT?

The main risks for AVAX Technologies, Inc. include the potential for clinical trial failures or delays, regulatory hurdles and approval delays, competition from other cancer therapies, and the company's ability to secure additional funding. As an OTC-listed company, AVXT also faces risks related to limited liquidity and transparency. The company's negative profit margin highlights its reliance on future funding or partnerships to sustain operations.